Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care medicaid population

Clinical Therapeutics

Volumn 26, Issue 9, 2004, Pages 1518-1532

  Hartung, Daniel M ^a,c   Touchette, Daniel R ^a   Ketchum, Kathy L ^a   Haxby, Dean G ^a   Goldberg, Bruce W ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b State of Oregon   (United States)

^c Portland or 97239 ^*  (United States)

Author keywords

celecoxib; drug policy; Medicaid; pharmacy benefits; prior authorization; quasi experimental design; reimbursement

Indexed keywords

CELECOXIB; PROTON PUMP INHIBITOR; ROFECOXIB;

ARTICLE; DATA ANALYSIS; DRUG LEGISLATION; DRUG UTILIZATION; EMERGENCY WARD; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INFORMATION RETRIEVAL; MANAGED CARE ORGANIZATION; MEDICAID; MEDICAL SERVICE; TIME SERIES ANALYSIS; UTILIZATION REVIEW;

ADULT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; ISOENZYMES; MALE; MANAGED CARE PROGRAMS; MEDICAID; MEMBRANE PROTEINS; MODELS, ECONOMIC; PRESCRIPTIONS, DRUG; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 9644265644     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.09.013     Document Type: Article

References (34)

1. Levit K., Smith C., and Cowan C. Trends in U.S. health care spending, 2001 Health Aff (Millwood) 22 2003 154 164
2. Altman S.H., and Parks-Thomas C. Controlling spending for prescription drugs N Engl J Med 346 2002 855 856
3. Rosenthal M.B., Berndt E.R., and Donohue J.M. Promotion of prescription drugs to consumers N Engl J Med 346 2002 498 505
4. Novartis Pharmacy Benefit Report 2000 Novartis Pharmaceutical Corp Parsippany, NJ
5. MacKinnon N.J., and Kumar R. Prior authorization programs: A critical review of the literature J Manage Care Pharm 7 2001 297 302
6. Olson B.M. Approaches to pharmacy benefit management and the impact of consumer cost sharing Clin Ther 25 2003 250 272
7. Eddy D.M. Clinical decision making: From theory to practice. Principles for making difficult decisions in difficult times JAMA 271 1994 1792 1798
8. Reinertsen J.L. Zen and the art of physician autonomy maintenance Ann Intern Med 138 2003 992 995
9. Soumerai S.B. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid Health Aff (Millwood) 23 2004 135 146
10. Soumerai S.B., Ross-Degnan D., Fortess E.E., and Abelson J. A critical analysis of studies of state drug reimbursement policies: Research in need of discipline Milbank Q 71 1993 217 252
11. White A.C. Jr, Atmar R.L., and Wilson J. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes Clin Infect Dis 25 1997 230 239
12. Smalley W.E., Griffin M.R., and Fought R.L. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients N Engl J Med 332 1995 1612 1617
13. Ray W.A. Policy and program analysis using administrative databases Ann Intern Med 127 1997 712 718
14. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
15. Spiegel B.M., Targownik L., Dulai G.S., and Gralnek I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 138 2003 795 806
16. International Classification of Diseases, Ninth Revision, Clinical Modification 6th ed 2003 US Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services Washington, DC
17. Raiford D.S., Perez Gutthann S., and Garcia Rodriguez L.A. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database Epidemiology 7 1996 101 104
18. Bright R.A., Avorn J., and Everitt D.E. Medicaid data as a resource for epidemiologic studies: Strengths and limitations J Clin Epidemiol 42 1989 937 945
19. Neter J., Kutner M.I.L., Nachtsheim C.J., and Wasserman W. Applied Linear Regression Models 3rd ed 1996 Irwin Chicago, Ill
20. Wagner A.K., Soumerai S.B., Zhang F., and Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 27 2002 299 309
21. Strom B.L., and Carson J.L. Use of automated databases for pharmacoepidemiology research Epidemiol Rev 12 1990 87 107
22. Available at: Oregon Department of Human Services, and Oregon Health Plan OHP managed care enrollment reports Accessed July 23, 2004 pubs/enrollment
23. Steinbrook R. The prescription-drug problem N Engl J Med 346 2002 790
24. Smalley W.E., Griffin M.R., Fought R.L., and Ray W.A. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs J Gen Intern Med 11 1996 461 469
25. Petersen L.A., Burstin H.R., and O'Neil A.C. Nonurgent emergency department visits: The effect of having a regular doctor Med Care 36 1998 1249 1255
26. Soumerai S.B., McLaughlin T.J., and Ross-Degnan D. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia N Engl J Med 331 1994 650 655
27. Gillings D., Makuc D., and Siegel E. Analysis of interrupted time series mortality trends: An example to evaluate regionalized perinatal care Am J Public Health 71 1981 38 46
28. Cook T.D., and Campbell D.T. Quasi-Experimentation: Design and Analysis Issues for Field Settings 1979 Rand McNally College Publishing Chicago, Ill
29. Veney J.E., and Kaluzny A.D. Evaluation and Decision Making for Health Services 1998 Health Administration Press Chicago, Ill
30. Hearst N., Grady D., Barron H.V., and Kerlikowske K. Research using existing data: Secondary data analysis, ancillary studies, and systematic reviews Hully S.B. Cummings S.R. Browner W.S. Designing Clinical Research 2nd ed 2001 Lippincott Williams & Wilkins Philadelphia, Pa 195 210
31. Momani A.A., Madhavan S.S., and Nau D.P. Impact of NSAIDs prior authorization policy on patients' QoL Ann Pharmacother 36 2002 1686 1691
32. Carson J.L., Ray W.A., and Strom B.L. Medicaid databases Strom B.L. Phannacoepidemiology 3rd ed 2000 Wiley New York 303 324
33. Sonnenblick E.H. Differences between COX-2-specific inhibitors: Clinical and economic implications Am J Manag Care 8 Suppl 15 2002 S428 S430
34. Wright J.M. The double-edged sword of COX-2 selective NSAIDs CMAJ 167 2002 1131 1137